Significant Share Conversion at Orion Corporation
Orion Corporation has recently completed an important share conversion process involving 49,164 of its shares. This conversion of A shares into B shares is a strategic move outlined in the company's Articles of Association, ensuring a smoother voting process and better governance.
Details on Share Structure
With this latest conversion, the total number of shares in Orion Corporation now stands at 141,134,278. Following the conversion, the company's share distribution consists of 31,841,817 A shares and 109,292,461 B shares. This restructuring allows for a total voting power of 746,128,801 votes among its shareholders, enhancing the decision-making capabilities of the company.
Leadership Insights
The leadership team at Orion Corporation continues to steer the ship towards growth and innovation in the pharmaceutical industry. The President and CEO, Liisa Hurme, along with General Counsel Mikko Kemppainen, are focused on ensuring that each strategic decision aligns with the company's long-term vision for well-being. With their guidance, Orion maintains a firm foothold in both the human and veterinary pharmacological sectors.
About Orion Corporation
For over a century, Orion Corporation has played a pivotal role in enhancing health and well-being across the globe. This Nordic pharmaceutical powerhouse develops, manufactures, and markets a diverse range of pharmaceuticals and active ingredients. The company boasts a portfolio of both proprietary and generic medications, alongside consumer health products.
The Core Business Areas
Orion's research and development efforts are concentrated on oncology and pain management, with proprietary products specifically designed to combat cancer, neurological ailments, and respiratory conditions. As a result of these advancements, Orion is positioned as a leader in these therapeutic areas.
Recent Financial Performance
In a testament to its growth and market presence, Orion's net sales in the most recent financial year reached EUR 1,542 million. This impressive figure underscores the company's commitment to excellence and innovation within the healthcare space. With approximately 3,700 dedicated professionals working globally, Orion remains focused on its mission to improve well-being through advanced healthcare solutions.
Contact Information
If you would like to learn more about Orion Corporation or the recent changes in share structure, you can reach out to Tuukka Hirvonen, the Head of Investor Relations, at +358 10 426 2721. For further information, Orion's official website is also a great resource.
Frequently Asked Questions
What is the main purpose of the share conversion at Orion Corporation?
The share conversion allows Orion to manage its voting rights and shareholder structure more effectively.
How many shares are currently outstanding after the conversion?
After the conversion, Orion Corporation has a total of 141,134,278 shares outstanding.
Who are the key executives at Orion Corporation?
The key executives include Liisa Hurme (President and CEO) and Mikko Kemppainen (General Counsel).
What are the core therapeutic areas of Orion's research and development?
Orion focuses on oncology and pain management among other health issues in its R&D efforts.
How has Orion Corporation performed financially recently?
In the latest financial year, Orion recorded net sales of EUR 1,542 million.
